NCT01399840

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Arm 1 will enroll patients with either AML or MDS; Arm 2 will enroll patients with either CLL or MCL.

Conditions

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Interventions

Type	Name	Description
DRUG	BMN 673	Oral capsule with multiple dosage forms given once daily

Timeline

• Start date: 2011-06-30
• Primary completion: 2014-03-31
• Completion: 2014-05-31
• First posted: 2011-07-22
• Last updated: 2017-09-15

Locations

7 sites across 2 countries: United States, United Kingdom